{"id":840698,"date":"2025-04-23T09:58:33","date_gmt":"2025-04-23T13:58:33","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/orchestra-biomed-announces-avim-therapy-focused-satellite-symposium-at-hrs-2025-annual-meeting\/"},"modified":"2025-04-23T09:58:33","modified_gmt":"2025-04-23T13:58:33","slug":"orchestra-biomed-announces-avim-therapy-focused-satellite-symposium-at-hrs-2025-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/orchestra-biomed-announces-avim-therapy-focused-satellite-symposium-at-hrs-2025-annual-meeting\/","title":{"rendered":"Orchestra BioMed Announces AVIM Therapy-Focused Satellite Symposium at HRS 2025 Annual Meeting"},"content":{"rendered":"<div class=\"mw_release\">\n<ul>\n<li style=\"text-align:justify\">\n          <em>FDA recently granted Breakthrough Device Designation to AVIM therapy for use in patients with uncontrolled hypertension at increased cardiovascular risk<\/em>\n        <\/li>\n<li style=\"text-align:justify\">\n          <em>HRS Satellite Symposium will feature leading experts in electrophysiology, hypertension management and heart failure <\/em>\n        <\/li>\n<li style=\"text-align:justify\">\n          <em>Presentations will detail clinical results from prior studies demonstrating AVIM therapy\u2019s ability to immediately, substantially and persistently reduce systolic blood pressure, as well as improve cardiac function<\/em>\n        <\/li>\n<li style=\"text-align:justify\">\n          <em>Symposium will also feature presentation on the BACKBEAT global pivotal study Orchestra BioMed is currently enrolling in strategic collaboration with Medtronic, plc (NYSE: MDT) <\/em>\n        <\/li>\n<\/ul>\n<p align=\"justify\">NEW HOPE, Pa., April  23, 2025  (GLOBE NEWSWIRE) &#8212; Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, \u201cOrchestra BioMed\u201d or the \u201cCompany\u201d), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced it will host an industry-sponsored satellite symposium at the Heart Rhythm Society (\u201cHRS\u201d) 2025 Annual Meeting, taking place April 24\u201327, 2025, in San Diego, California featuring recent advancements in the Company\u2019s atrioventricular interval modulation (\u201cAVIM\u201d) therapy program. The April 25<sup>th<\/sup>, 6:45 am PT symposium titled \u201c<em>The Future of Cardiac Pacing: Unlocking the Potential of Atrioventricular Interval Modulation (AVIM) Therapy<\/em>\u201d will convene leading electrophysiologists, hypertension and heart failure specialists to discuss the unmet need in hypertension, AVIM therapy mechanism of action, and growing body of clinical evidence supporting this novel therapy for the treatment of patients with uncontrolled hypertension who have increased cardiovascular risk with or without an indication for a pacemaker.<\/p>\n<p align=\"justify\">\u201cThe FDA\u2019s recent grant of Breakthrough Device Designation to AVIM therapy for the treatment of hypertension in patients with increased cardiovascular risk, regardless of whether they are indicated for a pacemaker, underscores the significant unmet need in higher risk patients as well as the strength of the clinical data generated to date on AVIM therapy,\u201d commented Vivek Reddy, M.D., Director of Cardiac Arrhythmia Services at The Mount Sinai Fuster Heart Hospital, Director of Electrophysiology for the Mount Sinai Health System, and Executive Chairman of the BACKBEAT Study Steering Committee. \u201cI\u2019m excited to chair the session at HRS alongside my esteemed colleagues to provide a comprehensive overview of the clinical evidence and mechanistic data supporting the potential for AVIM therapy to transform hypertension management in older, higher risk patient populations.\u201d<\/p>\n<p align=\"justify\">The U.S. Food and Drug Administration recently granted Breakthrough Device Designation (\u201cBDD\u201d) for AVIM therapy. Specifically, the BDD is for an implantable system (i.e., a pacemaker) to deliver AVIM therapy using conduction system pacing to reduce blood pressure in patients with increased 10-year atherosclerotic cardiovascular disease (\u201cASCVD\u201d) risk, preserved left ventricular systolic function, and uncontrolled hypertension, despite the use of anti-hypertensive medications or in patients who may have intolerance to anti-hypertensive medications. Orchestra BioMed estimates that there are over 7.7 million U.S. patients that meet the criteria for the BDD for AVIM therapy. Orchestra BioMed, in collaboration with Medtronic, is currently enrolling the BACKBEAT global pivotal study, an investigational device exemption (\u201cIDE\u201d) study evaluating AVIM therapy for the treatment of uncontrolled hypertension despite the use of anti-hypertensive medication in patients who have a dual-chamber pacemaker.<\/p>\n<p>\n        <strong>Satellite Symposium Details:<\/strong><\/p>\n<p>        <strong>Title:<\/strong> The Future of Cardiac Pacing: Unlocking the Potential of Atrioventricular Interval Modulation (\u201cAVIM\u201d) Therapy <br \/><strong>Date:<\/strong> Friday, April 25, 2025<br \/><strong>Time:<\/strong> 6:45-8:00am PT<br \/><strong>Location:<\/strong> Hilton San Diego Bayfront Hotel, Indigo Ballroom CG<\/p>\n<p>\n        <strong>Presentation Topics and Presenters Include:<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:5pt;margin-bottom:5pt;text-align:justify\">\n          <strong>The Future of Cardiac Pacing: Unmet Hypertension Need in Patients with Increased Cardiovascular Risk and Evidence Supporting AVIM Therapy Mechanism of Action<\/strong>, presented by<strong> Vivek Reddy, M.D.<\/strong>, Mount Sinai Hospital<\/li>\n<li style=\"margin-top:5pt;margin-bottom:5pt;text-align:justify\">\n          <strong>AVIM Therapy Impact on Hypertension: Results from the MODERATO I &amp; II Studies<\/strong>, presented by <strong>Prof. Karl-Heinz Kuck, M.D.<\/strong>, University Heart Center L\u00fcbeck<\/li>\n<li style=\"margin-top:5pt;margin-bottom:5pt;text-align:justify\">\n          <strong>AVIM Therapy Impact on Diastolic Dysfunction: Results from the MODERATO II Study<\/strong>, presented by<strong> Marat Fudim, M.D., M.H.S.\u200b<\/strong>, Duke University<\/li>\n<li style=\"margin-top:5pt;margin-bottom:5pt;text-align:justify\">\n          <strong>Rationale and Design of the BACKBEAT Global Pivotal Study<\/strong>, presented by<strong> Andrea Russo, M.D., FACC, FHRS, FAHA,<\/strong> Cooper University Hospital<\/li>\n<\/ul>\n<p align=\"justify\">\n        <strong>About Orchestra BioMed <\/strong><\/p>\n<p>Orchestra BioMed (Nasdaq: OBIO) is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships with leading medical device companies. Orchestra BioMed\u2019s partnership-enabled business model focuses on forging strategic collaborations with leading medical device companies to drive successful global commercialization of products it develops. Orchestra BioMed\u2019s lead product candidate is atrioventricular interval modulation (AVIM) therapy (also known as BackBeat Cardiac Neuromodulation Therapy (CNT\u2122)) for the treatment of hypertension, the leading risk factor for death worldwide. Orchestra BioMed is also developing the Virtue<sup>\u00ae<\/sup>\u00a0Sirolimus AngioInfusion\u2122 Balloon (SAB) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. Orchestra BioMed has a strategic collaboration with Medtronic, one of the largest medical device companies in the world, for development and commercialization of AVIM therapy for the treatment of hypertension in pacemaker-indicated patients, and a strategic partnership with Terumo, a global leader in medical technology, for development and commercialization of Virtue SAB for the treatment of artery disease. For further information about Orchestra BioMed, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hdeWYsZ3h73ou5zHrp-6PjtzGmZuWf3JaGnZUI4zTItDVZLJ_QxitJnyfFDC2vahvFfXEAuH-WidomNSm9aSb91rhqbEEdVOFNHcfUydI3wSYrVXUnzQm2mDzaAdWMeVqlgOL1Y_wyOTeEITjMvSI9aWfxDDhD4JUoU-0ozj5qvqzZX06sNNRyKlH29NqnFvH9ENsjRIqI5tZKcQUy3pgL0W1bmxHBClDm3jyLl0ZfW2TVRUzHRoORhqzJbQuDeYa972br48L4L2WSe__6enhudNHlcTxcfsq81mPLYlGW-s30Wt4n5o8VxCRIYFs_jdIa_QgKmEbb3tHOjNCGCMM7_9Ac4DwGoCC8JvCnjD8PYSUXpYeUXZKM4gn2YpX4gtEHMfjn5ZJCZrstwUMx5ZrxSGbGc4NwyVkXf5YU6OKwVk9dypTPQQad7tNQ7DrvafYViZtYSCS0duLClJ8o3qajwI_ouriP6XGIWsCVGw0WEi_jDYJpZ6X3kLNKqydoE5\" rel=\"nofollow\" target=\"_blank\">www.orchestrabiomed.com<\/a>, and follow us on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2thuPgLgMCa9l149RyPPV5GZZSx__JQoh-IZwIO6q6FWjVFbMBH3nmtDya9ZHm8jRDR9Kpdk3Z5nv3LzfQMYallMoOTGlEFsbxR5BjD8nffYpfwNx84Cy3mRpmZ2aryDAmSrhZp5jeF53Mjs54F0-qZe12H9FSnlA6YX-Q2UW8cfhT7wFUSQ38LjkARH3SEekBI3Z_MYVP2UvOjxyYzjhZ9C4lB0tw6a9ZQHgVfS3PdxCX5vQjVSFOCzqOKYuj67FfeZGrBB1B7ufyQ0zz6CAp9QGmHd_9kEOJudk-sPLeKIvlMDRr4PAHvOoVkf5EZfnUKgG_oQrIR4G0-DkM_dTit2JbiPojhnQaHgTysIzMh4Aa5nlaQ4FDRfzpPd3j1syPp7P-F3Dw81EVZ3tFBPLhZCiji486T2w-VMH3SbQa2bRbG3C8dQ9snCKXKIrLv_dJBX90Jtz83_1deteg9-mnxEgGutCDf7OYRDpYz8boc=\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>.<\/p>\n<p>\n        <strong>References to Websites and Social Media Platforms<\/strong>\n      <\/p>\n<p align=\"justify\">References to information included on, or accessible through, websites and social media platforms do not constitute incorporation by reference of the information contained at or available through such websites or social media platforms, and you should not consider such information to be part of this press release.<\/p>\n<p align=\"justify\">\n        <strong>About AVIM Therapy <\/strong>\n      <\/p>\n<p align=\"justify\">AVIM therapy is an investigational therapy compatible with standard dual-chamber pacemakers designed to substantially and persistently lower blood pressure. It has been evaluated in pilot studies in patients with hypertension who are also indicated for a pacemaker. MODERATO II, a double-blind, randomized pilot study, showed that patients treated with AVIM therapy experienced net reductions of 8.1 mmHg in 24-hour ambulatory systolic blood pressure (aSBP) and 12.3 mmHg in office systolic blood pressure (oSBP) at six months when compared to control patients. In addition to reducing blood pressure, clinical results using AVIM therapy demonstrate improvements in cardiac function and hemodynamics. The BACKBEAT (BradycArdia paCemaKer with atrioventricular interval modulation for Blood prEssure treAtmenT) global pivotal study will further evaluate the safety and efficacy of AVIM therapy in lowering blood pressure in patients who have systolic blood pressure above target despite anti-hypertensive medication and who are indicated for or have recently received a dual-chamber cardiac pacemaker.<\/p>\n<p align=\"justify\">\n        <strong>About the FDA Breakthrough Device Program<\/strong>\n      <\/p>\n<p align=\"justify\">The FDA Breakthrough Device Program, established in 2015, is designed to expedite the development, review, and potential market access of medical devices that may offer more effective treatment or diagnosis for life-threatening or irreversibly debilitating conditions. The designation provides manufacturers with prioritized FDA review and early, frequent interactions with agency experts to efficiently address development and regulatory considerations. Breakthrough status may also support streamlined reimbursement pathways, including eligibility for New Technology Add-on Payments (NTAP) and Transitional Pass-Through Payments (TPT), by helping to demonstrate substantial clinical improvement.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements <\/strong>\n      <\/p>\n<p align=\"justify\">\n        <em>Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as \u201cbelieve,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cestimate,\u201d \u201ccontinue,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cexpect,\u201d \u201cshould,\u201d \u201cwould,\u201d \u201cplan,\u201d \u201cpredict,\u201d \u201cpotential,\u201d \u201cseem,\u201d \u201cseek,\u201d \u201cfuture,\u201d \u201coutlook\u201d and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements relating to the initiation, enrollment, timing, implementation and design of the Company\u2019s planned and ongoing pivotal trials, realizing the clinical and commercial value of AVIM therapy and Virtue SAB, and the potential safety and efficacy of the Company\u2019s product candidates, including the ability of AVIM therapy to favorably influence ventricular function, implementation of the Company\u2019s ongoing BACKBEAT global pivotal study, the potential benefits of BDD, including its ability to expedite FDA reviews and streamline reimbursement pathways,. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the Company\u2019s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on as a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and may differ from assumptions. Many actual events and circumstances are beyond the control of the Company. These forward-looking statements are subject to a number of risks and uncertainties, including changes in domestic and foreign business, market, financial, political, and legal conditions; risks related to regulatory approval of the Company\u2019s commercial product candidates and ongoing regulation of the Company\u2019s product candidates, if approved; the timing of, and the Company\u2019s ability to achieve expected regulatory and business milestones; the impact of competitive products and product candidates; and the risk factors discussed under the heading \u201cItem 1A. Risk Factors\u201d in the Company\u2019s annual report on Form 10-K for the year ended December 31, 2024, which was filed with the Securities and Exchange Commission on March 31, 2025, and under the heading \u201cItem1A. Risk Factors\u201d in Part II of the Company\u2019s subsequently filed quarterly reports on Form 10-Q.<\/em>\n      <\/p>\n<p align=\"justify\">\n        <em>The Company operates in a very competitive and rapidly changing environment. New risks emerge from time to time. Given these risks and uncertainties, the Company cautions against placing undue reliance on these forward-looking statements, which only speak as of the date of this press release. The Company does not plan and undertakes no obligation to update any of the forward-looking statements made herein, except as required by law.<\/em>\n      <\/p>\n<p align=\"justify\">\n        <strong>Investor Contact<\/strong><br \/>\n        <br \/>Jeremy Feffer<br \/>LifeSci Advisors<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hCKtAR3PagNsS5SVD7-gEpKnQc6Py7AA2LuJ57F5YCE9n8KysKE5Gs-plQRBSWHwa4gLmKLwdulqTk4WlmjMJ72_q5rUkkn3yo3pQvS5GtF3YGVIw2Hw7JSpIGYBfIM9\" rel=\"nofollow\" target=\"_blank\">Jfeffer@lifesciadvisors.com<\/a><\/p>\n<p align=\"justify\">\n        <strong>Media Contact<\/strong><br \/>\n        <br \/>Kelsey Kirk-Ellis<br \/>Orchestra BioMed<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=M4CxnvuMoiv7W7zIoRw4kHl--dy6ugfoqbAEzaCOolIwzz5sil2tRpbpOf1bT5wN8bZ7FpeB4xIQx0CCrKg2VlC6UZcHUhvXD7GzGat2Sorm18enjk6F7RA6xKXXTVv0\" rel=\"nofollow\" target=\"_blank\">kkirkellis@orchestrabiomed.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQzNzM2MiM2ODk5NzU0IzIxOTQwMTk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MWU2NmRhZDQtMzU2NS00YmYwLWFmNjYtZTFlNTBmODNkMjJjLTEyMDU1NzItMjAyNS0wNC0yMy1lbg==\/tiny\/Orchestra-BioMed-Holdings-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>FDA recently granted Breakthrough Device Designation to AVIM therapy for use in patients with uncontrolled hypertension at increased cardiovascular risk HRS Satellite Symposium will feature leading experts in electrophysiology, hypertension management and heart failure Presentations will detail clinical results from prior studies demonstrating AVIM therapy\u2019s ability to immediately, substantially and persistently reduce systolic blood pressure, as well as improve cardiac function Symposium will also feature presentation on the BACKBEAT global pivotal study Orchestra BioMed is currently enrolling in strategic collaboration with Medtronic, plc (NYSE: MDT) NEW HOPE, Pa., April 23, 2025 (GLOBE NEWSWIRE) &#8212; Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, \u201cOrchestra BioMed\u201d or the \u201cCompany\u201d), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced it &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/orchestra-biomed-announces-avim-therapy-focused-satellite-symposium-at-hrs-2025-annual-meeting\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Orchestra BioMed Announces AVIM Therapy-Focused Satellite Symposium at HRS 2025 Annual Meeting&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-840698","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Orchestra BioMed Announces AVIM Therapy-Focused Satellite Symposium at HRS 2025 Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/orchestra-biomed-announces-avim-therapy-focused-satellite-symposium-at-hrs-2025-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Orchestra BioMed Announces AVIM Therapy-Focused Satellite Symposium at HRS 2025 Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"FDA recently granted Breakthrough Device Designation to AVIM therapy for use in patients with uncontrolled hypertension at increased cardiovascular risk HRS Satellite Symposium will feature leading experts in electrophysiology, hypertension management and heart failure Presentations will detail clinical results from prior studies demonstrating AVIM therapy\u2019s ability to immediately, substantially and persistently reduce systolic blood pressure, as well as improve cardiac function Symposium will also feature presentation on the BACKBEAT global pivotal study Orchestra BioMed is currently enrolling in strategic collaboration with Medtronic, plc (NYSE: MDT) NEW HOPE, Pa., April 23, 2025 (GLOBE NEWSWIRE) &#8212; Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, \u201cOrchestra BioMed\u201d or the \u201cCompany\u201d), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced it &hellip; Continue reading &quot;Orchestra BioMed Announces AVIM Therapy-Focused Satellite Symposium at HRS 2025 Annual Meeting&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/orchestra-biomed-announces-avim-therapy-focused-satellite-symposium-at-hrs-2025-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-23T13:58:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQzNzM2MiM2ODk5NzU0IzIxOTQwMTk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/orchestra-biomed-announces-avim-therapy-focused-satellite-symposium-at-hrs-2025-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/orchestra-biomed-announces-avim-therapy-focused-satellite-symposium-at-hrs-2025-annual-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Orchestra BioMed Announces AVIM Therapy-Focused Satellite Symposium at HRS 2025 Annual Meeting\",\"datePublished\":\"2025-04-23T13:58:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/orchestra-biomed-announces-avim-therapy-focused-satellite-symposium-at-hrs-2025-annual-meeting\\\/\"},\"wordCount\":1603,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/orchestra-biomed-announces-avim-therapy-focused-satellite-symposium-at-hrs-2025-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQzNzM2MiM2ODk5NzU0IzIxOTQwMTk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/orchestra-biomed-announces-avim-therapy-focused-satellite-symposium-at-hrs-2025-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/orchestra-biomed-announces-avim-therapy-focused-satellite-symposium-at-hrs-2025-annual-meeting\\\/\",\"name\":\"Orchestra BioMed Announces AVIM Therapy-Focused Satellite Symposium at HRS 2025 Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/orchestra-biomed-announces-avim-therapy-focused-satellite-symposium-at-hrs-2025-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/orchestra-biomed-announces-avim-therapy-focused-satellite-symposium-at-hrs-2025-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQzNzM2MiM2ODk5NzU0IzIxOTQwMTk=\",\"datePublished\":\"2025-04-23T13:58:33+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/orchestra-biomed-announces-avim-therapy-focused-satellite-symposium-at-hrs-2025-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/orchestra-biomed-announces-avim-therapy-focused-satellite-symposium-at-hrs-2025-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/orchestra-biomed-announces-avim-therapy-focused-satellite-symposium-at-hrs-2025-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQzNzM2MiM2ODk5NzU0IzIxOTQwMTk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQzNzM2MiM2ODk5NzU0IzIxOTQwMTk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/orchestra-biomed-announces-avim-therapy-focused-satellite-symposium-at-hrs-2025-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Orchestra BioMed Announces AVIM Therapy-Focused Satellite Symposium at HRS 2025 Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Orchestra BioMed Announces AVIM Therapy-Focused Satellite Symposium at HRS 2025 Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/orchestra-biomed-announces-avim-therapy-focused-satellite-symposium-at-hrs-2025-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Orchestra BioMed Announces AVIM Therapy-Focused Satellite Symposium at HRS 2025 Annual Meeting - Market Newsdesk","og_description":"FDA recently granted Breakthrough Device Designation to AVIM therapy for use in patients with uncontrolled hypertension at increased cardiovascular risk HRS Satellite Symposium will feature leading experts in electrophysiology, hypertension management and heart failure Presentations will detail clinical results from prior studies demonstrating AVIM therapy\u2019s ability to immediately, substantially and persistently reduce systolic blood pressure, as well as improve cardiac function Symposium will also feature presentation on the BACKBEAT global pivotal study Orchestra BioMed is currently enrolling in strategic collaboration with Medtronic, plc (NYSE: MDT) NEW HOPE, Pa., April 23, 2025 (GLOBE NEWSWIRE) &#8212; Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, \u201cOrchestra BioMed\u201d or the \u201cCompany\u201d), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced it &hellip; Continue reading \"Orchestra BioMed Announces AVIM Therapy-Focused Satellite Symposium at HRS 2025 Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/orchestra-biomed-announces-avim-therapy-focused-satellite-symposium-at-hrs-2025-annual-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2025-04-23T13:58:33+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQzNzM2MiM2ODk5NzU0IzIxOTQwMTk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/orchestra-biomed-announces-avim-therapy-focused-satellite-symposium-at-hrs-2025-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/orchestra-biomed-announces-avim-therapy-focused-satellite-symposium-at-hrs-2025-annual-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Orchestra BioMed Announces AVIM Therapy-Focused Satellite Symposium at HRS 2025 Annual Meeting","datePublished":"2025-04-23T13:58:33+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/orchestra-biomed-announces-avim-therapy-focused-satellite-symposium-at-hrs-2025-annual-meeting\/"},"wordCount":1603,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/orchestra-biomed-announces-avim-therapy-focused-satellite-symposium-at-hrs-2025-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQzNzM2MiM2ODk5NzU0IzIxOTQwMTk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/orchestra-biomed-announces-avim-therapy-focused-satellite-symposium-at-hrs-2025-annual-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/orchestra-biomed-announces-avim-therapy-focused-satellite-symposium-at-hrs-2025-annual-meeting\/","name":"Orchestra BioMed Announces AVIM Therapy-Focused Satellite Symposium at HRS 2025 Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/orchestra-biomed-announces-avim-therapy-focused-satellite-symposium-at-hrs-2025-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/orchestra-biomed-announces-avim-therapy-focused-satellite-symposium-at-hrs-2025-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQzNzM2MiM2ODk5NzU0IzIxOTQwMTk=","datePublished":"2025-04-23T13:58:33+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/orchestra-biomed-announces-avim-therapy-focused-satellite-symposium-at-hrs-2025-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/orchestra-biomed-announces-avim-therapy-focused-satellite-symposium-at-hrs-2025-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/orchestra-biomed-announces-avim-therapy-focused-satellite-symposium-at-hrs-2025-annual-meeting\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQzNzM2MiM2ODk5NzU0IzIxOTQwMTk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQzNzM2MiM2ODk5NzU0IzIxOTQwMTk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/orchestra-biomed-announces-avim-therapy-focused-satellite-symposium-at-hrs-2025-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Orchestra BioMed Announces AVIM Therapy-Focused Satellite Symposium at HRS 2025 Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/840698","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=840698"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/840698\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=840698"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=840698"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=840698"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}